Venous System Articles & Analysis
19 news found
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). ...
“The use of the Surfacer System enabled us to quickly and efficiently obtain central venous access after two previous attempts to recanalize the central vein occlusion using other approaches were ...
“The Surfacer Inside-out system represents a new approach to restore right-sided central venous access in chronic thoracic venous occlusion by the inside-out recanalization technique” stated Dr. ...
“We appreciate the ongoing support of our loyal shareholders and the trust new investors have placed in the company as it underscores their commitment and alignment with our vision to improve central venous access related patient outcomes and reduce healthcare costs.” The Surfacer System employs the novel Inside-Out approach and is the first FDA ...
About Advanced Medical Solutions s.r.o: Advanced Medical Solutions develops, produces, and distributes integrative solutions (devices, sw+ services) for the early and non-invasive diagnostics and therapy of arterial, venous and lymphatic systems with a specific focus on diabetic patients and other groups with cardiovascular risk factors. ...
Wayne, PA, December 20, 2021 –Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced the completion of enrollment in its pivotal study – Venous stent for the Iliofemoral Vein Investigational clinical trial using the Vesper DUO Venous Stent System® (VIVID). ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a case report demonstrating the ability to utilize the Surfacer® System to perform the Inside-Out® procedure and obtain right-sided central venous access in a patient ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report three cases where the Surfacer System was used to help facilitate the placement of the HeRO graft in patients with thoracic central venous obstruction (TCVO) where ...
As a result of this decision, hospitals and ambulatory surgery centers (ASCs) will be able to utilize HCPCS code C9780 to report the Inside-Out procedure when performed with the Surfacer System beginning on October 1, 2021. The Surfacer System employs a novel Inside-Out approach and is the first FDA cleared medical device to facilitate upper body central ...
Prior the procedure described in the paper, the patient was implanted with a leadless pacemaker system due to unsuccessful attempts to gain central venous access using a recanalization procedure. ...
I have long had a passion for the importance of specifically designed and studied technology for peripheral vascular disease treatment,” stated Stacy Enxing Seng. “The Duo Venous Stent system and the VIVID Trial are clearly designed with the improvement of deep venous disease treatment in mind. ...
The Vesper DUO Stent System is designed to be the next generation venous stent technology, uniquely engineered to address the challenges of deep vein obstruction. ...
The objective of the SAVE Registry was to report Surfacer Inside-Out® Access Catheter System device performance and safety information for patients with thoracic central venous obstruction (TCVO) requiring central venous access. ...
Food and Drug Administration (FDA) approved Investigational Device Exemption (IDE) study was designed to evaluate the performance and safety of the Surfacer Inside-Out® Access Catheter System (Surfacer System) when used to facilitate central venous access in patients with thoracic central venous obstructions. The results of ...
The study is utilizing the VASCADE MVP Venous Vascular Closure System, which received U.S. Food and Drug Administration (FDA) approval in late 2018. VASCADE MVP is the only marketed vascular closure system proven and labeled specifically for procedures requiring multiple access site venous closure with 6-12 French inner diameter ...
Initial findings of an early feasibility trial have demonstrated that the LimFlow System does represent a safe and reproducible method of treating patients with no-option critical limb ischaemia (CLI). ...
Haenel et al. administered the stem cells retrograde through the heart’s venous system, precisely to the area in need of regeneration. This retrograde injection technique, combined with a temporary blockage of the coronary vein at the level of a previous arterial occlusion, allowed the stem cells to overcome the endothelial barrier and thereby created a ...
. - October 30, 2019 - Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that positive results from the AMBULATE pivotal study demonstrating the safety and efficacy of the company’s VASCADE® MVP Venous Vascular Closure System compared to manual compression were published online in the Journal of the American College ...
Food and Drug Administration (FDA) for the VASCADE® MVP Venous Vascular Closure System. VASCADE MVP is the first and only vascular closure system designed and labeled specifically for multi-site venous closure – for 6-12 French inner diameter sheaths. ...